aTyr Pharma announces interim analysis from Phase 2 EFZO-CONNECT

aTyr Pharma (ATYR) announced findings from an interim analysis of eight patients in the ongoing Phase 2 EFZO-CONNECT study evaluating its lead therapeutic candidate, efzofitimod, in patients with limited or diffuse systemic sclerosis-related interstitial lung disease. Key findings to date for efzofitimod include: Stable or improved mRSS for all patients and an improvement of 4 points or greater for three out of four efzofitimod-treated patients with diffuse SSc-ILD, where the minimal clinically important differenc is a 4 to 6 point improvement at 12 months; Preliminary signals of improvement for inflammatory biomarkers including interferon gamma and monocyte chemoattractant protein-1 and disease biomarkers Krebs von den Lungen-6 and surfactant protein-D; Generally safe and well tolerated at all doses, with no treatment related serious adverse events